Antiplatelet Effects in Stroke-Patients

Overview

Many patients suffer from acute and chronic pain. The incidence of chronic pain correlates with increased age. Most of patients rely on analgesic medication to control the pain. Dipyrone is an extensively used drug in Western and Eastern Europe as well as Central and South America, largely due to its favorable analgesic and antipyretic effects in conjunction with a low incidence of gastrointestinal complications when compared to other non-steroidal anti-inflammatory drugs (NSAIDs). Aspirin is the backbone of antiplatelet therapy in patients after ischemic stroke. However, it is known that there are substantial inter-individual response variabilities to antiplatelet medication. Furthermore, patients with impaired response to aspirin have a significant higher risk of recurrent cerebrovascular events. The investigators have recently shown that co-medication with aspirin and dipyrone in patients with coronary artery disease lead to insufficient antiplatelet effects of aspirin. The incidence of chronic pain is very high in patients with ischemic stroke. Therefore, in this study the investigators aim to examine, if co-medication of aspirin and dipyrone interaction also occurs in patients after ischemic stroke.

Full Title of Study: “Dipyrone Nullifies Aspirin Antiplatelet Effects in Stroke-Patients”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 2015

Clinical Trial Outcome Measures

Primary Measures

  • Laboratory response to aspirin therapy in metamizole co-medicated Stroke patients
    • Time Frame: Baseline

Secondary Measures

  • Major adverse cardiac and cerebrovascular events (MACCE Events) during hospital stay
    • Time Frame: participants are followed until discharge up to 4 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Age ≥ 18 years – Patients with ischemic stroke and ASS-medication (80-320 mg/day) with/without analgesic comedication Exclusion Criteria:

  • Reanimation – cardiogenic shock

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Heinrich-Heine University, Duesseldorf
  • Provider of Information About this Clinical Study
    • Principal Investigator: Klinik für Kardiologie, Pneumologie und Angiologie, Division of Cardiology, Pulmonary Diseases, Vascular Medicine – Heinrich-Heine University, Duesseldorf
  • Overall Official(s)
    • Amin Polzin, MD, Principal Investigator, Klinik für Kardiologie, Pneumologie und Angiologie, Universtiätsklinikum Düsseldorf
    • Tobias Zeus, MD, Study Chair, Klinik für Kardiologie, Pneumologie und Angiologie, Universtiätsklinikum Düsseldorf

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.